Denemek ALTIN - Özgür
Australia develops tool to identify dust lung disease risk
BioSpectrum Asia
|BioSpectrum Asia Feb 2024
A new dust testing methodology developed by Australia-based University of Queensland researchers offers workers better protection from diseases such as black lung and silicosis.
-
The escalating prevalence of dust lung diseases, especially among young Australians, have made the scientific community realise a new approach was needed. Exposure monitoring for dust and silica is currently based on the weight of particles but this overlooks many details
Bu hikaye BioSpectrum Asia dergisinin BioSpectrum Asia Feb 2024 baskısından alınmıştır.
Binlerce özenle seçilmiş premium hikayeye ve 9.000'den fazla dergi ve gazeteye erişmek için Magzter GOLD'a abone olun.
Zaten abone misiniz? Oturum aç
BioSpectrum Asia'den DAHA FAZLA HİKAYE
BioSpectrum Asia
The Race to Build Singapore's Biotech Unicorns
MIRXES, known for its work in early cancer detection and backed by A*STAR and the National University of Singapore, became Southeast Asia's first biotech unicorn when it listed on the Hong Kong Exchange in 2025.
5 mins
BioSpectrum Asia Feb 2026
BioSpectrum Asia
"Neuroinflammation is not only a hallmark of Alzheimer's disease but a key pathological feature in other neurodegenerative disorders"
As dementia becomes the leading cause of death in Australia and Alzheimer’s disease continues to affect millions worldwide, the urgency for fundamentally new treatment strategies has never been clearer.
4 mins
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Leprosy Isn't Over: South-East Asia's Unfinished Fight
As we commemorate World Leprosy Day on January 25, the global community is oldest diseases-has not yet been consigned to history.
2 mins
BioSpectrum Asia Feb 2026
BioSpectrum Asia
"Absence of a widespread infectious disease emergency in 2025 has hindered progress in combating AMR"
After decades of incremental antibiotic innovation, antimicrobial resistance (AMR) is outpacing our ability to respond, and 2026 may mark a breaking point.
5 mins
BioSpectrum Asia Feb 2026
BioSpectrum Asia
The Strategic Rise of India's Deep-Science Economy
India is emerging as a powerful hub for deep science and biotechnology, driven by favourable geopolitics, a large domestic market, strong pharmaceutical and chemicals infrastructure, and supportive government policies.
4 mins
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Japan strengthening biopharma capabilities
Asia's biopharma landscape is shifting rapidly toward innovation, with countries such as South Korea, Singapore, India, and Taiwan advancing R&D capabilities.
7 mins
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Cancer Diagnosis, Accelerated by AI
Cancer remains a leading cause of death worldwide, with Asia bearing a disproportionate burden.
13 mins
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Beyond Companion Diagnostics: How Biomarkers and Digital Technologies Will Reshape Oncology Care in Asia by 2026
The oncology landscape in Asia stands at a critical juncture.
5 mins
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Pharma M&A set to boom in 2026
After years of unspectacular Mergers and Acquisitions (M&A) activity, 2025 recorded some of the largest pharma deals.
3 mins
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Seeing Opportunity in Ophthalmology
Asia-Pacific is emerging as one of the most active regions for ophthalmology innovation. In recent months, a wave of cross-border partnerships and licensing deals has underscored both the scale of unmet need in eye disease and the region's growing ambition to play a larger role in treatment development. From glaucoma and retinal disorders to dry eye disease and childhood myopia, companies across pharma, biotech, and medtech are increasingly accelerating clinical progress.
6 mins
BioSpectrum Asia Jan 2026
Listen
Translate
Change font size